HCV Disease Progression
Coffee May Reduce Fibrosis in People with Fatty Liver Disease
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 07 February 2012 00:00
- Written by Liz Highleyman
A new study published in the February 2012 issue of Hepatology adds to the evidence that drinking caffeinated coffee may help slow or prevent progression of liver damage, this time in people with nonalcoholic fatty liver disease (NAFLD).
Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels
- Details
- Category: Acute Hepatitis C
- Published on Tuesday, 07 February 2012 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people who take the HCV protease inhibitor boceprevir (Victrelis) for hepatitis C treatment along with a ritonavir-boosted HIV protease inhibitor may experience drug-drug interactions that reduce concentrations of both drugs to ineffective levels, Merck warned this week.
Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 03 January 2012 00:00
- Written by Press Release
Bristol-Meyers Squibb's investigational anti-cancer drug brivanib did not improve overall survival of patients with hepatocellular carcinoma (HCC) who were unable to take or did not respond to sorafenib (Nexavar) in the Phase 3 BRISK-PS trial, the company recently reported. The drug is still being tested in other patients populations.
European Study Does Not See Rapid Long-Term Liver Fibrosis in HIV/HCV Coinfected People
- Details
- Category: Acute Hepatitis C
- Published on Tuesday, 31 January 2012 00:00
- Written by Liz Highleyman
People who are already HIV positive when they acquire hepatitis C virus (HCV) may not experience unusually rapid liver disease progression over the long term, even though the fibrosis progression rate may appear high during the acute stage of infection, according to a European FibroScan study described in the February 15, 2012, issue of Clinical Infectious Diseases.
EACS 2011: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People
- Details
- Category: Fibrosis & Cirrhosis
- Published on Monday, 17 October 2011 00:00
- Written by Liz Highleyman
Earlier initiation of antiretroviral therapy (ART) and spending more time on HIV treatment may help slow liver disease progression in HIV/HCV coinfected patients, according to an Italian study using non-invasive methods presented at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.
More Articles...
- ICAAC 2011: Interferon May Reduce Liver Disease Progression in HIV/HCV Coinfected Relapsers
- ICAAC 2011: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People
- HCV Can Be Sexually Transmitted Between HIV+ Men
- Gene Variation Linked to Liver Cancer in Hepatitis C Patients
Web Design and Development by